Effects of low molecular weight galactomannans based standardized fenugreek seed extract in subjects with high fat mass: A randomized, double-blind, placebo-controlled clinical study

ABSTRACT

The present investigation evaluated the effects of low molecular weight galactomannans-based standardized fenugreekseeds extract (LMWGAL-TF) on human subjects with high-fat mass for 8-weeks using a prospective, randomized,double-blind, placebo-controlled design. Twenty-four subjects with percent body fat were randomized to ingest acapsule of LMWGAL-TF (500 mg, once a day) or the matching placebo at a 11 ratio for 8 weeks. The outcomemeasurements were recorded at baseline, week-4, and week-8 (end of the treatment). The efficacy outcome includedfat mass (absolute, non-fat mass and %) by skinfold thickness method (along with triceps, suprailiac, and abdominal)and bioelectrical impedance analysis method, body weight, body mass index, and abdominal girth. The standardsafety parameters were measured, such as adverse events, vital signs, hematology, and biochemistry. Eight weeksof LMWGAL-TF supplementation showed significant reduction in suprailiac skinfold thickness (v/s baseline) andabdominal skinfold thickness (v/s baseline and v/s placebo), and percent fat mass, (v/s baseline). The LMWGAL-TFsupplementation was found to be safe and well-tolerated. In conclusion, LMWGAL-TF supplementation showedsafety and efficacy in reducing skinfold thickness (abdominal and suprailiac) and percent body fat in subjects with ahigh fat mass